Skip to main content

Advertisement

SpringerLink
Log in

Clusterin as a Diagnostic and Prognostic Marker for Transitional Cell Carcinoma of the Bladder

  • Published:
Pathology & Oncology Research

Abstract

We investigated the feasibility of profiling and measuring the concentration of clusterin in urine and serum for individuals with transitional cell carcinoma (TCC) of the bladder and comparing it with nontumor controls. In addition, we analyzed the correlation of expression of clusterin in specimens of TCC to various clinicopathologic parameters and prognosis of bladder cancer. Blood and urine samples were used from 68 patients with TCC of the bladder and from 61 patients with benign urological diseases. Enzyme-linked immunosorbent assays (ELISA) were performed for clusterin from serum and urine. Quantitation of clusterin mRNA was carried out in 68 bladder tumor specimens from radical cystectomy or transurethral resection and 26 normal bladder specimens from BPH patients by using RT-PCR method. Correlation for the expression of clusterin mRNA with clinicopathologic parameters was analyzed. Serum and urine clusterin was significantly higher in individuals with bladder cancer than control (p = 0.001). Sensitivity and specificity of serum and urine clusterin as a tumor marker for TCC of the bladder was found to be 80%, 91%, 87.1% and 96.7% respectively. Clusterin expression was significantly higher in TCC specimens than normal tissue specimens (P < 0.001). Expression of clusterin was significantly higher in patients with invasive TCC of the bladder than that in patients with superficial TCC and control (P < 0.001). Overexpression of clusterin mRNA was significantly associated with tumor recurrence and overall survival (p < 0.001). The recurrence-free survival time of patients with overexpression of clusterin was significantly shorter than that of patients with weak expression of clusterin (9.8 months vs. 35.2 months). Clusterin may be considered as a potential diagnostic and prognostic biomarker for bladder cancer using urine, serum and/or molecular biology techniques.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Irani J, Heidenreich A, Mottet N et al (2008) What is new in bladder cancer diagnosis and management? Eur Urol supplements 7:484–493

    Article  Google Scholar 

  2. Haitel A, Posch B, El-Baz M et al (2001) Bilharzial related organ confined muscle-invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, e-cadherin, epidermal growth factor receptor and c-erbB-2. J Urol 165:1481–1487

    Article  CAS  PubMed  Google Scholar 

  3. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J et al (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 164:680–684

    Article  CAS  PubMed  Google Scholar 

  4. Cajulis RS, Haines GK 3rd, Frias-Hidvegi D et al (1995) Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn. Cytopathol. 13(3):214–224

    Article  CAS  PubMed  Google Scholar 

  5. Schmitz-Dräger BJ, Fradet Y, Grossman HB (2008) Bladder cancer markers in patient management: the current perspective. World J Urol 26:1–3

    Article  PubMed  Google Scholar 

  6. Blaschuk O, Burdzy K, Fritz IB (1983) Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem. 258:7714–7720

    CAS  PubMed  Google Scholar 

  7. Jenne DE, Tschopp J (1992) Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci. 17:154–159

    Article  CAS  PubMed  Google Scholar 

  8. Jones SE, Jomary C (2002) Clusterin. Int J Biochem Cell Biol. 34:427–431

    Article  CAS  PubMed  Google Scholar 

  9. Shannan B, Seifert M, Leskov K et al (2006) Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death and Differentiation J. 13:12–19

    Article  CAS  Google Scholar 

  10. Parczyk K, Pilarsky C, Rachel U et al (1994) Gp80 (Clusterin: TRPM-2) mRNA levels is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 120:186–188

    Article  CAS  PubMed  Google Scholar 

  11. Steinberg J, Oyasu R, Lang S et al (1997) Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3:1707–1711

    CAS  PubMed  Google Scholar 

  12. Redondo M, Villar E, Torres-Muñoz J et al (2000) Overexpression of Clusterin in human breast carcinoma. Am J Pathol 157:393–399

    CAS  PubMed  Google Scholar 

  13. Miyake H, Gleave M, Kamidono S et al (2002) Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 50:150–154

    Article  Google Scholar 

  14. Krüger S, Mahnken A, Kausch I et al (2006) Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 67(1):105–109

    Article  PubMed  Google Scholar 

  15. Epstein JI, Amin MB, Reuter VR et al (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22:1435–1448

    Article  CAS  PubMed  Google Scholar 

  16. Park J, Park J, Ju S et al (2003) Clusterin mRNA expression in apoptotic and activated rat thymocytes. Cell Research 13(1):49–58

    Article  CAS  PubMed  Google Scholar 

  17. Petrie A, Sabin C (2005) Medical Statistics at a Glance. 2nd ed.,Blackwell Publishing

  18. Trougakso IP, So A, Jansen B et al (2004) Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64:1834–1842

    Article  Google Scholar 

  19. Gleave M, Miyake H (2005) Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J. Urol. 23:38–46

    Article  CAS  PubMed  Google Scholar 

  20. Wong P, Ulyanova T, Organisciak DT et al (2001) Expression of multiple forms of clusterin during light-induced retinal degeneration. Curr Eye Res 23:157–165

    Article  CAS  PubMed  Google Scholar 

  21. Leskov KS, Klokov DY, Li J et al (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 278:11590–11600

    Article  CAS  PubMed  Google Scholar 

  22. Pucci S, Bonanno E, Pichiorri F et al (2004) Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23:2298–2304

    Article  CAS  PubMed  Google Scholar 

  23. Chen X, Halberg RB, Ehrhardt WM et al (2003) Clusterin as a biomarker in murine and human intestinal neoplasia. Proc. Natl. Acad. Sci. USA 100:9530–9535

    Article  CAS  PubMed  Google Scholar 

  24. Saffer H, Wahed A, Rassidakis GZ et al (2002) Clusterin expression in malignant lymphomas. Mod. Pathol. 15:1221–1223

    Article  PubMed  Google Scholar 

  25. Stejskal D, Fiala RR (2006) Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma. 53(4):343–346

    CAS  PubMed  Google Scholar 

  26. Miyake H, Hara I, Gleave ME et al (2004) Protection of androgen dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 61:318–323

    Article  CAS  PubMed  Google Scholar 

  27. Zellweger T, Kiyama S, Chi K et al (2003) Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int. 92:463–469

    Article  CAS  PubMed  Google Scholar 

  28. Scaltriti M, Brausi M, Amorosi A (2004) Clusterin (SGP-2, APOJ) expression is downregulated in low- and high-grade human prostate cancer. Int. J. Cancer 108:23–30

    Article  CAS  PubMed  Google Scholar 

  29. July LV, Beraldi E, So A et al (2004) Nucleotide-based therapies targeting clusterin chemosensitized human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3:223–232

    CAS  PubMed  Google Scholar 

  30. Zhang LY, Ying WT, Mao YS (2003) Loss of clusterin both in serum and tissue correlates with the tumorigenesis of oesophageal squamous cell carcinoma via proteomic approaches. World J Gastroenterol 9:650–654

    CAS  PubMed  Google Scholar 

  31. Xie MJ, Motoo Y, Su SB et al (2002) Expression of clusterin in human pancreatic cancer. Pancreas 25:234–238

    Article  PubMed  Google Scholar 

  32. Miyake H, Hara I, Kamidono S et al (2001) Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 7:4245–4252

    CAS  PubMed  Google Scholar 

  33. Miyake H, Nelson C, Rennie PS et al (2000) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2, in prostate cancer xenograft models. Cancer Res 60:2547–2554

    CAS  PubMed  Google Scholar 

  34. Miyake H, Chi KN, Gleave ME (2000) Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgenindependent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6:1655–1663

    CAS  PubMed  Google Scholar 

  35. Miyake H, Hara I, Kamidono S et al (2001) Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes up-regulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. Int J Urol 8:337–349

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pathology Department, Tanta University, Tanta, Egypt

    Sahar M. Hazzaa

  2. Urology Department, Tanta University, Tanta, Egypt

    Osama M. Elashry

  3. Microbiology Department, Tanta University, Tanta, Egypt

    Ibtesam K. Afifi

Authors
  1. Sahar M. Hazzaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Osama M. Elashry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ibtesam K. Afifi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Osama M. Elashry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hazzaa, S.M., Elashry, O.M. & Afifi, I.K. Clusterin as a Diagnostic and Prognostic Marker for Transitional Cell Carcinoma of the Bladder. Pathol. Oncol. Res. 16, 101–109 (2010). https://doi.org/10.1007/s12253-009-9196-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-009-9196-3

Keywords

Search

Navigation